

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



China Resources Medical Holdings Company Limited

華潤醫療控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

(1) RESIGNATION OF NON-EXECUTIVE DIRECTOR

AND

(2) APPOINTMENT OF NON-EXECUTIVE DIRECTOR

AND MEMBER OF THE AUDIT COMMITTEE

RESIGNATION OF NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Director(s)**”) of China Resources Medical Holdings Company Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) hereby announces that Mr. WANG Yan (“**Mr. WANG**”) has resigned, with effect from August 25, 2021, as a non-executive Director and a member of the audit committee of the Company (the “**Audit Committee**”) due to other work arrangement. Mr. WANG has confirmed that he has no disagreement with the Board and that there is no matter in respect of his resignations which needs to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

The Board hereby expresses its gratitude to Mr. WANG for his valuable efforts and contributions to the Group during his tenure of office as the non-executive Director and member of the Audit Committee.

APPOINTMENT OF NON-EXECUTIVE DIRECTOR AND MEMBER OF THE AUDIT COMMITTEE

The Board announces that Mr. SHAN Baojie (“**Mr. SHAN**”) has been appointed as a non-executive Director and a member of the Audit Committee with effect from August 25, 2021.

Mr. SHAN, aged 50, obtained a master degree in Accounting from Renmin University of China (中國人民大學) in Beijing in June 2002 and a bachelor degree in Chemistry from Wuhan University (武漢大學) in Wuhan in July 1992. Mr. SHAN is currently the vice general manager of China Resources Healthcare Group Limited (“**CR Healthcare**”) and also taking the office as a director of a number of its subsidiaries. CR Healthcare, as one of the primary healthcare platform of the China Resources Group, is specialised in the investment and operations management in the healthcare industry. CR Healthcare is committed to the long-term development of China’s medical and healthcare services, actively participates in China’s medical system reform, and has proactively explores and involves in the investment, operation and management of hospitals and healthcare industries in the PRC. In addition to being the single largest shareholder of the Company, CR Healthcare also operates and manages a number of medical institutions in certain provinces of China including Liaoning, Jiangxi, Yunnan and Guangdong and Guangxi, etc. Prior to joining CR Healthcare, Mr. SHAN was with the Group since 2011 as the executive general manager and then the vice general manager, and he was also an executive Director of the Company from February 2016 to November 2016. He had served in a variety of roles at the State Food and Drug Administration from 1998 to 2011. Mr. SHAN also completed a training program at the World Health Organization in 2007, where he gained experience in the U.S. pharmaceutical supervision and management system. From July 1992 to July 1998, Mr. Shan worked in the general manager’s office of the Northeast Pharmaceutical Group Co., Ltd. (東北製藥集團公司).

Mr. SHAN has entered into a service agreement with the Company for a term of three years from August 25, 2021, which can be terminated by either party by giving to the other party not less than one month’s notice in writing. Mr. SHAN will not be entitled to any remuneration from the Group in respect of his appointment as a non-executive Director.

Pursuant to the articles of association of the Company and the Corporate Governance Code as set out in Appendix 14 to the Rules Governing Listing of Securities on the Stock Exchange (the “**Listing Rules**”), Mr. SHAN will hold office as a non-executive Director until the next general meeting of the Company and will be subject to the retirement by rotation and re-election at that meeting.

Save as disclosed in this announcement, Mr. SHAN (i) did not hold any directorship in other listed companies in Hong Kong or overseas in the past three years; (ii) does not hold any other positions within the Company and other members of the Group; (iii) does not have any relationship with any Directors, senior management, or substantial or controlling shareholders (as defined in the Listing Rules) of the Company; and (iv) does not have any other major appointments or professional qualifications.

As at the date of this announcement, Mr. SHAN does not have any interests or underlying in the shares of the Company pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Save as disclosed in this announcement, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. SHAN that need to be brought to the attention of the Shareholders and the Stock Exchange.

The Board hereby extends its warmest welcome to Mr. SHAN for his new appointment.

By order of the board of
China Resources Medical Holdings Company Limited
CHENG Libing
Executive Director and Chief Executive Officer

Beijing, August 25, 2021

As at the date of this announcement, the Board comprises Mr. SONG Qing, Mr. CHENG Libing, Ms. REN Yuan and Ms. FU Yanjun as executive Directors; Mr. SHAN Baojie as non-executive Director; Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Ms. CHIU Kam Hing Kathy and Mr. LEE Kar Chung Felix as independent non-executive Directors.